Remove Drug Research Remove Marketing Remove Pharmaceutical Companies
article thumbnail

The Cost of Knowledge: Evaluating Open vs. Paid Data for Pharma

DrugBank

These data sources are known for being highly referenced and usable for specific research activities; further yet, a number of recognizable open sources, along with their identifiers, are considered industry standard resources.

article thumbnail

An Evolving Regulatory Environment for Rare and Orphan Diseases

Advarra

The Orphan Drug Act of 1983 was instrumental in changing the number of orphan drugs approved in the U.S. The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drug research and development.

Disease 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

The Pharma Data

Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization.

article thumbnail

Accelerating Drug Discovery Through Repurposing

DrugBank

CMap utilizes gene expression profiles to connect drugs, genes, and diseases, enabling researchers to identify potential repurposing candidates based on their transcriptional signatures. Thalidomide : Initially marketed as a sedative in the late 1950s, thalidomide was withdrawn from the market due to its severe teratogenic effects.

article thumbnail

Using clinical genomics and AI in drug development to elevate success

Drug Target Review

Drug development: addressing complexity and success rates Drug development is a complex and expensive process, requiring multidisciplinary expertise and high-risk financial investments. The major hurdles that pharmaceutical companies face are long lead times, high costs and a low probability of success (PoS).